Halozyme Therapeutics, Inc. $HALO Shares Sold by Mutual of America Capital Management LLC

Key Points

• Mutual of America Capital Management LLC reduced its ownership in Halozyme Therapeutics by 44.4% in the second quarter, now holding 61,279 shares valued at approximately $3.2 million.
• Halozyme's recent earnings report showed an EPS of $1.54, exceeding analyst expectations, with revenue up 40.8% year-over-year at $325.72 million.
• Wall Street analysts have downgraded Halozyme's stock ratings recently, resulting in an average rating of “Hold” and a price target of $72.89.

Mutual of America Capital Management LLC decreased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 44.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 61,279 shares of the biopharmaceutical company's stock after selling 48,963 shares during the quarter. Mutual of America Capital Management LLC's holdings in Halozyme Therapeutics were worth $3,188,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of HALO. Wealth Preservation Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the first quarter worth about $32,000. SVB Wealth LLC purchased a new position in shares of Halozyme Therapeutics in the first quarter worth about $33,000. Bessemer Group Inc. lifted its stake in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 207 shares in the last quarter. Brooklyn Investment Group lifted its stake in shares of Halozyme Therapeutics by 1,558.1% in the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 670 shares in the last quarter. Finally, Park Place Capital Corp lifted its stake in shares of Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after buying an additional 182 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $66.89 on Friday. The company's 50 day simple moving average is $71.73 and its 200-day simple moving average is $62.25. The company has a market capitalization of $7.82 billion, a price-to-earnings ratio of 15.31, a price-to-earnings-growth ratio of 0.35 and a beta of 1.16. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $79.50. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business's revenue was up 40.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Zacks Research downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 6th. Leerink Partners raised shares of Halozyme Therapeutics from an "underperform" rating to a "market perform" rating and set a $70.00 price target on the stock in a research note on Tuesday, October 14th. Leerink Partnrs raised shares of Halozyme Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, October 14th. Finally, The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Halozyme Therapeutics has an average rating of "Hold" and an average price target of $72.89.

Insider Activity

In other news, CFO Nicole Labrosse sold 2,227 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the sale, the chief financial officer directly owned 22,079 shares of the company's stock, valued at approximately $1,721,058.05. The trade was a 9.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares in the company, valued at $50,648,622.57. This trade represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 108,227 shares of company stock valued at $7,779,595. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.